Treatment of bypass failure in patients with chronic limb threatening ischemia – open surgery vs. percutaneous mechanical thrombectomy
Abstract
Summary:Background: Lower limb bypass occlusion in patients with chronic limb threating ischemia remains a challenge. We can choose between different treatment options: open surgery, local thrombolysis, thrombectomy/atherectomy devices. In this pilot study, we compare clinical outcomes and treatment costs between open surgery (OS) and percutaneous mechanical thrombectomy (pMTH). Patients and methods: This pilot study represents a retrospective analysis of hospital data of 48 occluded bypasses admitted from 2013 to 2018. Only patients presenting with severe ischemia and recrudescence of symptoms (Rutherford 4–6) were included in the current analysis. Two cohorts of patients were analysed: patients who underwent OS and patients that underwent pMTH. Primary clinical outcomes were one-year cumulative patency and limb salvage rates. Total cost was calculated as a sum of intra- and post-operative costs. To weigh clinical benefits against the economic consequences of OS versus pMTH a cost-effectiveness framework was adopted. Results: We analysed a series of 48 occluded bypasses 17 treated with open surgery and 31 with pMTH. Procedural success was 100% in both groups. When comparing one-year death rates (p-value = .22) and re-occlusion rates (p-value = .43), no statistically significant differences were observed between the two cohorts. Mean patency duration in the surgery cohort was significantly shorter (p-value < .05). Primary patency (OS 41.2% vs. pMTH 48.4%) and limb salvage rate (OS 88.2% vs. pMTH 90.3%) at one year are similar in both groups. The total cost of surgery was substantially higher (OS 10,159€ vs. pMTH 8,401€) Conclusions: This pilot study, although limited to 48 occluded bypasses, demonstrates that endovascular treatment with pMTH is less invasive, less time consuming and less expensive, and produces greater health benefits than traditional OS.
References
1 Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010;51(5):52–68.
2 . A multi-modal approach to management of bypass graft failure. Vasc Med. 1998;3:251–70.
3 . Secondary bypass after infrainguinal bypass graft failure. Semin Vasc Surg. 2009;22:234–9.
4 Long-term outcome after early infrainguinal graft failure. J Vasc Surg. 1997;26:425–38.
5 Tissue loss, early primary graft occlusion, female gender and a prohibitive failure rate of secondary infrainguinal arterial reconstruction. J Vasc Surg. 2002;35:902–9.
6 . Follow-up of infrainguinal graft thrombolysis. Arch Surg. 2003;138:198–202.
7 . Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion. Vasc Health Risk Manag. 2012;8:603–10.
8 . Secondary femoropopliteal reconstruction. Ann Surg. 1981;193:35–42.
9 Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg. 1996;172:105–12.
10 . A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Artery Surgery (TOPAS) Investigators. N Eng J Med. 1998;338:1105–11.
11 . Thrombolysis for lower extremity bypass graft occlusions. J Vasc Surg. 2011;54:339–44.
12 . Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of lower extremity. Ann Surg. 1994;220:251–68.
13 . Recanalization of acute and subacute venous and synthetic bypass-graft occlusion with mechanical rotational catheter. Cardiovasc Intervent Radiol. 2013;36:936–42.
14 . Repeat leg bypass after multiple prior bypass failure. J Vasc Surg. 1994;19:268–77.
15 . Preferred strategies for secondary infrainguinal bypass: lesson learned from 300 consecutive reoperations. J Vasc Surg. 1995;21:282–95.
16 . Lysis/balloon angioplasty versus thrombectomy/open patch angioplasty of failed femoropopliteal polytetrafluoroethylene bypass grafts. J Vasc Surg. 2002;35:307–15.
17 Early experience with a rotational thrombectomy device for treatment of acute and subacute infra-aortic arterial occlusions. J Endovasc Ther. 2003;10:322–31.
18 Long-term results after recanalization of acute and subacute thrombotic acclusions of the infra-aortic arteries and bypass-grafts using a rotational thrombectomy device. Fortschr Rontgenstr. 2002;174:1559–65.
19 . Treatment of acute femoropoplitel bypass graft occlusion: comparison of mechanical rotational thrombectomy with ultrasound-enhanced lysis. Fortschr Rontgenstr. 2008;180:547–52.
20 . Twelve months outcome after percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion. Cardiovasc Interv and Ther. 2012;28:178–83.
21 . The outcome of occluded above-knee femoropopliteal prostheses implanted for critical ischaemia. Eur J Vasc Endovasc Surg. 2006;32:680–5.
22 Thrombolysis of occluded infrainguinal vein grafts: predictors of outcome. J Vasc Surg. 1997;25:1023–32.
23 . Patient survival and limb prognosis after arterial embolectomy. Eur J Vasc Surg. 1987;1:263–71.
24 Outcome of catheter-directed thrombolysis for lower extremity arterial bypass occlusion. J Vasc Surg. 2003;37:72–8.
25 Redo infrainguinal bypass: factors predicting patency and limb salvage. Ann Vasc Surg. 2003;17:492–502.
26 Cost-effectiveness of percutaneous transluminal angioplasty (PTA) versus vascular surgery in limb-threatening ischaemia. Int J Angiol. 2000;4:214–19.
27 . A primer on cost-effectiveness analyses for vascular surgeons. J Vasc Surg. 2012;55:1794–1800.
28 . A retrospective cost analysis of angioplasty compared to bypass surgery for lower limb arterial disease in an Australian tertiary health service. J Med Imaging Radiat Oncol. 2018;62:337–44.
29 . Cost analysis of initial treatment with endovascular revascularization, open surgery or primary major amputation in patients with peripheral artery disease. J Endovascv Ther. 2018;25:504–11.
30 Treating peripheral artery disease in the wake of rising costs and protracted length of stay. Ann Vasc Surg. 2017;44:253–60.